Generic Fosamax Plus D

At this time, generic Fosamax Plus D is not available in the United States. The medication is currently under the protection of a patent that prevents any generic versions from being manufactured. As soon as the patent expires in June 2013, however, other drug companies may begin manufacturing generic Fosamax Plus D products.

Generic Fosamax Plus D: An Overview

Fosamax Plus D™ (alendronate and cholecalciferol) is a prescription medication used for osteoporosis. It is part of a group of medications known as bisphosphonates.
 
Fosamax Plus D is made by Merck & Co., Inc. It is currently under the protection of a patent that prevents any generic Fosamax Plus D from being manufactured in the United States.
 

When Will Generic Fosamax Plus D Be Available?

The first patents for Fosamax Plus D are currently set to expire in June 2013. This is the earliest predictable date that a generic version of the drug could become available.
 
However, other circumstances could come up to extend or shorten the exclusivity period. This could include such things as other patents for specific Fosamax Plus D uses or lawsuits. There have already been several lawsuits examining the issue of Fosamax patents, and more lawsuits are likely to occur. Once the patents expire and any lawsuits are resolved, several companies will likely begin manufacturing generic Fosamax Plus D.
  

Is Alendronate and Cholecalciferol the Same as Generic Fosamax Plus D?

No -- alendronate and cholecalciferol are the active ingredients in Fosamax Plus D, but they are not a generic version of it. What can be confusing is that, oftentimes, the active ingredient of any drug is referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.
 
Written by/reviewed by: Kristi Monson, PharmD; Arthur Schoenstadt, MD
Last reviewed by: Kristi Monson, PharmD;
Other Articles in This eMedTV Presentation